专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013166233A1 SYSTEM AND METHOD FOR AUTOMATED DETERMINATION OF THE RELATIVE EFFECTIVENESS OF ANTI-CANCER DRUG CANDIDATES 审中-公开
标题翻译：用于自动确定抗癌药物候选药物相对有效性的系统和方法
公开(公告)号：WO2013166233A1
公开(公告)日：2013-11-07
申请号：PCT/US2013/039189
申请日：2013-05-02
申请人： DIATECH ONCOLOGY
发明人： PERREE, Mathieu , HALLQUIST, Allan, E. , PETIT, Olivier
IPC分类号： G06F19/00
CPC分类号： G01N33/5011 , G01N33/5044 , G06F19/704 , G06F19/709
摘要： A computer system is provided for determining the relative effectiveness of anti-cancer drugs. The interface has selectable options, including an option to manage drug testing parameters, and enables user selection of desired drug testing parameters in relation to a virtual well plate associated with a physical well plate of a spectrophotometer. The computer system causes the spectrophotometer to start a drug test, wherein the physical well plate includes at least one test well containing viable cancer cells; and at least one drug candidate in a predetermined concentration; and at least one control well containing the viable cancer cells alone. The system records the optical density of the well at a predetermined wavelength at selected time intervals for a selected duration of time, and stores the optical density and time measurements in the database. An activity value is calculated from the optical density and time measurements, and a correlation is displayed between the activity value and the drug candidate's ability to induce apoptosis in the cancer cells.
摘要翻译：提供了一种计算机系统来确定抗癌药物的相对有效性。该界面具有可选择的选项，包括管理药物测试参数的选项，并且使用户可以选择相关于与分光光度计的物理井板相关联的虚拟井板所需的药物测试参数。计算机系统使得分光光度计开始药物测试，其中物理井板包括至少一个含有活的癌细胞的测试孔; 和至少一种预定浓度的候选药物; 以及含有单独存活的癌细胞的至少一个对照孔。该系统以选定的时间间隔将预定波长的阱的光密度记录在选定的时间内，并将光密度和时间测量值存储在数据库中。从光密度和时间测量计算活性值，并且在活性值和药物候选物诱导癌细胞凋亡的能力之间显示相关性。

2. 发明申请

WO2013172955A9 TUMOR CELL ISOLATION/PURIFICATION PROCESS AND METHODS FOR USE THEREOF 审中-公开
公开(公告)号：WO2013172955A9
公开(公告)日：2013-11-21
申请号：PCT/US2013/031300
申请日：2013-03-14
申请人： DIATECH ONCOLOGY
发明人： PRESANT, Cary , PERREE, Mathieu , HALLQUIST, Allan
IPC分类号： G01N33/574 , G01N33/15 , C12N5/07
摘要： Methods of isolating and purifying hematologic or non-hernatologic tumor cells useful a variety of assays and procedures, including tumor drug efficacy screening such as Microcuiture Kinetic assays, are disclosed herein. Further, Microcuiture Kinetic assays and methods suitable for comparing the relative efficacy of generic versus proprietary anti-cancer drugs are also disclosed.

3. 发明申请

WO2015171848A2 SYNERGISM AND ANTAGONISM BETWEEN MULTIPLE ANTI-CANCER AGENTS DETERMINED BY MICK ASSAY 审中-公开
标题翻译： MICK测定确定的多种抗癌药物之间的协同作用和拮抗作用
公开(公告)号：WO2015171848A2
公开(公告)日：2015-11-12
申请号：PCT/US2015/029589
申请日：2015-05-07
申请人： DIATECH ONCOLOGY, LLC
发明人： PRESANT, Cary , PERREE, Mathieu , HALLQUIST, Allan
CPC分类号： G01N33/5011 , G01N2500/10 , G01N2800/7028
摘要： Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient. Additionally, methods of identifying a drug candidate that increases or decreases the effectiveness of another drug candidate in an individual patient is provided, wherein an increase or a decrease in apoptosis produced by the drug combination compared to the apoptosis produced by the drug candidate alone is indicative of an increase or decrease in effectiveness, respectively.
摘要翻译：提供了使用MiCK测定来确定个体患者最有效的候选药物的方法。另外，提供鉴定增加或降低个体患者中另一候选药物的有效性的药物候选物的方法，其中药物组合产生的细胞凋亡与仅由候选药物产生的细胞凋亡相比增加或减少是指示性的分别增加或减少有效性。

4. 发明申请

WO2015164560A1 INTERTUMORAL HOMOGENEITY DETERMINED BY MICK ASSAY 审中-公开
标题翻译：由MICK测定确定的间质均质
公开(公告)号：WO2015164560A1
公开(公告)日：2015-10-29
申请号：PCT/US2015/027210
申请日：2015-04-23
申请人： DIATECH ONCOLOGY, LLC
发明人： PRESANT, Cary , PERREE, Mathieu , HALLQUIST, Allan
IPC分类号： C12Q1/02 , G01N9/00 , G01N33/487 , G01N33/50 , C12N5/09
CPC分类号： G01N33/5011 , G01N33/57423 , G01N33/57438
摘要： The use of genomic tests shows variability between the primary tumor and the metastases in most circumstances referred to as tumor heterogeneity. Since it is unduly invasive and difficult to obtain samples from the primary and metastatic tumors within a patient, a need exists for a method of testing chemotherapeutic effectiveness in a patient that is applicable to both primary tumor and metastases. Provided are methods of using the MiCK assay to determine the most effective drug candidate(s) for an individual patient by testing a single tumor site. In a further embodiment, the kinetic unit (KU) value obtained by analysis of cancer cells from a tumor site in an individual patient in the presence of a drug candidate is within two standard deviations of the KU value obtained by analysis of a different tumor site in the patient in the presence of the same drug candidate.
摘要翻译：基因组测试的使用显示在大多数情况下被称为肿瘤异质性的原发性肿瘤与转移瘤之间的变异性。由于患者内的原发性和转移性肿瘤获得样本是不适当的侵入性和难以获得的，因此需要一种在适用于原发性肿瘤和转移瘤的患者中测试化学治疗有效性的方法。提供了使用MiCK测定法通过测试单个肿瘤部位来确定个体患者最有效的候选药物的方法。在另一个实施方案中，通过在候选药物存在下从个体患者的肿瘤部位分析癌细胞获得的动力学单元（KU）值是通过分析不同肿瘤部位获得的KU值的两个标准偏差在同一候选药物存在的情况下。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式